KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Shares Outstanding data on record, last reported at $122.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 33.51% year-over-year to $122.0 million; the TTM value through Dec 2025 reached $122.0 million, up 33.51%, while the annual FY2025 figure was $122.0 million, 33.51% up from the prior year.
  • Shares Outstanding reached $122.0 million in Q4 2025 per AQST's latest filing, roughly flat from $121.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $122.0 million in Q4 2025 and bottomed at $36.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $71.0 million, with a median of $64.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: increased 7.92% in 2021, then soared 61.79% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $41.2 million in 2021, then skyrocketed by 32.98% to $54.8 million in 2022, then rose by 25.0% to $68.5 million in 2023, then surged by 33.39% to $91.4 million in 2024, then surged by 33.51% to $122.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $122.0 million in Q4 2025, $121.7 million in Q3 2025, and $99.4 million in Q2 2025.